Hansa secures the money inventory model round 232 Msek/US 24.3 million {dollars} And restructuring the money owed of Novaquest.
In comparison with the earlier yr, IDEFirix merchandise elevated by 76 %.
Lund, Swedenand July 17, 2025 / PRNEWSWIRE/- Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), immediately introduced its non permanent report for the month of January- immediatelyJune 2025.
René Agoyiar Lukander, CEO, Hansa very important He stated, “Within the second quarter of 2025, the corporate succeeded in acquiring further financing and restructuring the present debt settlement with Novaquest, guaranteeing the flexibility to report information on two principal section packages in kidney transplantation, and fight GBM traces. Europe“
Monetary efficiency
In Q2 2025, Hansa has accomplished a rise in profitable capital with the assist of recent and present shareholders. Funding will assist experimental readings from the third stage within the second half of 2025, together with the central expertise of kidney transplantation and the Good-IDD-02 expertise in GBM management.
As a part of a guided arrow case, Hansa and Novaquest entered right into a modified debt settlement through which the corporate compensates us 14.9 million {dollars} From the suspended money owed by issuing new shares (property rights). The remaining money owed might be paid in mounted money funds in June 2027and June 2028 and June 2029. As well as, there may be virtually actual fee to us 14.9 million {dollars} due to January 31, 2026Which will be settled in money or property rights in keeping with the corporate’s estimate.
IDEFirX Q2 merchandise elevated by 76 % in comparison with the identical interval final yr. In Q2 2025, the corporate offered 47.8 Msek in IDEFirix gross sales that replicate a rise of 76 % in comparison with the earlier yr (27.2 Msek) in the identical time interval. For 1H 2025, IDEFirix 113.5 MSEK gross sales represented a 52 % improve in product gross sales over 1 hour 2024, which represents about 80 % of merchandise gross sales for a full yr for 2024.
The pipeline is obtainable
The corporate remains to be heading in the right direction to report information from a 20-Hedaydy-17 (belief) examine. It’s anticipated to submit a organic license request (BLA) to the US Meals and Drug Administration (FDA) within the second half 2025, after studying the information.
Constructive information was offered by the 15-Hesse-09 experiment within the second stage, together with evaluating oblique therapy, with the examine of the outcomes of the worldwide Guillain-Barré syndrome (IGOS) on the annual assembly of the ocean nerve affiliation (PNS) in Could.
Registration continues in GNT-018-Mide, Stage 2 Expertise in Crigler carpenter To evaluate the effectiveness and integrity of the genetic remedy of the GNT-0003 after pre-processing with IMLIFIDASE. Stage 1b SRP-9001-104 with Sarepta stays on the suitable path to learn uncooked information later this yr.
Abstract
Msek, except it’s said in any other case – uninterrupted
Q2 2025
Q2 2024
1H 2025
1H 2024
revenue
49.1
34.3
115.5
90.3
– Product gross sales 1
47.8
27.2
113.5
74.7
SG & A.
(90.5)
(88.2)
(166.5)
(179.5)
Analysis and improvement bills
(95.8)
(91.7)
(160.1)
(194.6)
Loss from operations
(154.8)
(187.4)
(248.2)
(346.8)
Loss for this era
(178.9)
(207.9)
(216.0)
(426.5)
Internet money utilized in operations
(111.7)
(189.2)
(263.6)
(378.3)
Money investments and quick -term investments
354.4
705.0
354.4
705.0
EPS earlier than and after dilution (SEK)
(2.53)
(3.30)
(3.13)
(7.38)
The variety of excellent shares
84,763,222
67,814,241
84,763,222
67,814,241
The typical variety of shares weighing earlier than and after dilution
70,802,763
62,929,675
68,937,930
57,800,736
The variety of staff on the finish of the interval
140
146
140
146
1 Complete product gross sales within the second quarter 2024 reached 47.1 Msek. Gross sales had been compensated by a ruling of a complete of 19.9 Msek for capabilities The credit related to quantity reductions and restoration of potential restoration quantities. The whole product gross sales within the first half of 2024 reached 94.6 Msek The ruling, which is nineteen.9 Msek. Safi of the decision, the full gross sales of the product within the first half reached 74.7 Msek.
Collective name particulars
Hansa Biopharma will host a cellphone convention on Thursday, July 17, 2025in 14:00 CEST / / 8:00 AM East US time.
The occasion will host René Agoyiar Lukander, CEO, Evan BaltinCFO, Hitto Kaufmann, CSTO, Maria Törnsén Coo and Pressident Us The decision will embody a overview of non permanent outcomes, enterprise modernization and pipelines. It is going to be held in English.
The slides used within the presentation might be broadcast on the corporate’s web site through the name under Events and presentations It would even be offered on-line after the decision.
To take part within the phone convention, please use the applying particulars talked about under: Participated in Toll Free: 1-833-821-3542 Worldwide cellphone name to contributors in: 1-412-652-1248 *Please ask to affix Hansa Biopharma name
Hansa Biopharma AB is a number one pharmaceutical pharmaceutical firm in a mission to develop and market progressive therapies, save life and alter life for sufferers with uncommon immunodeficiency. The corporate has a wealthy analysis, improvement and enlargement program based mostly on its Cleaving Expertise, to satisfy the damaging medical wants that aren’t worn in autoimmune ailments, genetic remedy and implant. The corporate’s IMLIFIDASE’s portfolio, which is the primary immune enzyme therapy (IGG) in its class, which has been confirmed to have the ability to implant kidney in sufferers who had been very appointed and HNSA-5487, is from the following technology of IGG with infiltration. Hansa Biopharma is positioned in Lund, SwedenIt has operations in Europe America is listed in Nasdak Stockholm beneath the HNSA index. Discover out extra in www.hansabiopharma.com And we adopted LinkedIn.
